ArticleAnnals of translational medicine2021
Exosomal miRNA-223-3p as potential biomarkers in patients with cerebral small vessel disease cognitive impairment.
Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Brain-Derived Extracellular Vesicle Subpopulations: from Bulk Measurements to Single-Entity Assays.JACS Au · 2026Review
- Exosomes: emerging biomarkers and therapeutic potential in postoperative delirium and postoperative cognitive dysfunction.Frontiers in cell and developmental biology · 2026Review
- Review
- MicroRNAs Detected in Whole Blood Following Traumatic Brain Injury Are Associated with Recovery 6 Months after Injury.Neurotrauma reports · 2025Article
- Roles of neuroimaging markers and biomarkers in cerebral small vessel disease and their associations with cognitive function.Frontiers in neurology · 2025Review
- Mesenchymal Stem Cells-Derived Exosomal miR-223-3p Alleviates Ocular Surface Damage and Inflammation by Downregulating Fbxw7 in Dry Eye Models.Investigative ophthalmology & visual science · 2024Article
- Potential biomarkers for cerebral small vessel disease with cognitive impairment: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2024Review
- Emerging role of mesenchymal stem cells-derived extracellular vesicles in vascular dementia.Frontiers in aging neuroscience · 2024Review
- Molecular biomarkers for vascular cognitive impairment and dementia.Nature reviews. Neurology · 2023Review
- Insight into extracellular vesicles in vascular diseases: intercellular communication role and clinical application potential.Cell communication and signaling : CCS · 2023Review
- A Scoping Review on Biomarkers of Endothelial Dysfunction in Small Vessel Disease: Molecular Insights from Human Studies.International journal of molecular sciences · 2023Article
- Article
- Exosomal miR-320e as a Novel Potential Biomarker for Cerebral Small Vessel Disease.International journal of general medicine · 2023Article
- Diagnostic value of plasma D-dimer and serum lipoprotein phospholipase A2 in patients with cerebral small vessel disease and their association with severity of the disease.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrovascular disease is a common clinical illness. Many patients with cerebrovascular disease can be accompanied by cognitive impairment. The exosomal microRNA (miRNA)-223-3p is related to vascular endothelial injury, synaptic function, inflammatory response, and other mechanisms. In this study, we investigated the levels of plasma exosomal miRNA-223-3p in patients with cerebral small vessel disease (CSVD), in order to determine whether it could be used as a more accessible potential biomarker for the early diagnosis and treatment of CSVD. This study aimed to explore whether the development of cognitive impairment can be explained by differentially expressed miRNA-223-3p by detecting the level of miRNA-223-3p, which is abundant in peripheral blood exosomes related to cognitive impairment in CSVD.
methodsThe three groups of participants included 40 patients with CSVD cognitive impairment (CSVDCI), 38 patients with CSVD, and 35 normal controls (NC). The real-time polymerase chain reaction (RT-PCR) was used to detect the expression level of blood exosomal miRNA-223-3p. In addition, we also studied the relationship between exosomal miRNA-223-3p and blood Hcy and C-reactive protein (CRP). Receiver-operating characteristic (ROC) curve analysis was used to evaluate the diagnostic efficacy of plasma exosomal miRNA-223-3p.
resultsThe expression of exosomal miRNA-223-3p in CSVD increased, and the expression of miRNA-223-3p increased significantly with the occurrence of cognitive impairment. Exosomal miRNA-223-3p was positively correlated with the expression levels of Hcy and CRP in the blood.
conclusionsThe expression of plasma exosomal miRNA-223-3p is associated with the development of cognitive impairment in patients with CSVD. It may be involved in the pathogenesis of CSVD and cognitive impairment, and can be used as a sensitive predictive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.